K.J. Harrison & Partners Inc Invests $2.03 Million in Natera, Inc. $NTRA

K.J. Harrison & Partners Inc acquired a new stake in shares of Natera, Inc. (NASDAQ:NTRA) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 8,850 shares of the medical research company’s stock, valued at approximately $2,027,000.

Several other hedge funds have also recently modified their holdings of the stock. Swedbank AB increased its holdings in shares of Natera by 6.7% during the fourth quarter. Swedbank AB now owns 48,184 shares of the medical research company’s stock valued at $11,038,000 after acquiring an additional 3,014 shares in the last quarter. SBI Securities Co. Ltd. increased its holdings in shares of Natera by 15.9% during the fourth quarter. SBI Securities Co. Ltd. now owns 502 shares of the medical research company’s stock valued at $115,000 after acquiring an additional 69 shares in the last quarter. Alpha Cubed Investments LLC acquired a new position in shares of Natera in the 4th quarter valued at $206,000. Morse Asset Management Inc acquired a new position in shares of Natera in the 4th quarter valued at $402,000. Finally, QRG Capital Management Inc. raised its position in Natera by 168.9% during the 4th quarter. QRG Capital Management Inc. now owns 12,507 shares of the medical research company’s stock worth $2,865,000 after buying an additional 7,855 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera News Summary

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Quarterly results beat expectations: Natera reported $0.35 EPS and $665.5M revenue, well above consensus — this outperformance supports upside in the stock. Earnings and company page
• Positive Sentiment: Analyst support is generally constructive: several firms have recent Buy/Outperform notes and the consensus target (~$253.47) sits above current levels, which can attract momentum buyers. Analyst coverage
• Positive Sentiment: Institutional inflows noted (new/expanded stakes by firms such as Robinhood Asset Management and JPMorgan), indicating larger investors remain interested in the growth story. Institutional holdings
• Neutral Sentiment: Multiple insiders (CEO Steven Chapman, CFO Michael Brophy, John Fesko, Solomon Moshkevich) sold shares in early May under pre‑arranged Rule 10b5‑1 plans to cover tax withholding on vesting awards; these are scheduled, limited reductions rather than opportunistic dumps. Insider trades summary
• Negative Sentiment: Fundamentals still show profitability headwinds: Natera reports a negative net margin and negative ROE, and analysts model a negative EPS for the fiscal year, which leaves valuation and path‑to‑sustained profitability as open risks. Financial metrics and estimates

Insiders Place Their Bets

In other news, CFO Michael Burkes Brophy sold 482 shares of the firm’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $210.49, for a total transaction of $101,456.18. Following the sale, the chief financial officer directly owned 57,496 shares in the company, valued at $12,102,333.04. This trade represents a 0.83% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Solomon Moshkevich sold 3,405 shares of the firm’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $203.69, for a total value of $693,564.45. Following the sale, the insider owned 142,295 shares in the company, valued at $28,984,068.55. This trade represents a 2.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 38,266 shares of company stock valued at $7,747,808 over the last quarter. Insiders own 5.63% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have weighed in on NTRA. Wall Street Zen raised Natera from a “hold” rating to a “buy” rating in a research report on Saturday, April 18th. Citigroup began coverage on Natera in a research report on Wednesday, January 7th. They set a “buy” rating and a $300.00 price target on the stock. Morgan Stanley cut their price target on Natera from $265.00 to $250.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 3rd. Canaccord Genuity Group reaffirmed a “buy” rating on shares of Natera in a research report on Monday, January 12th. Finally, William Blair began coverage on Natera in a research report on Tuesday, April 14th. They set an “outperform” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $253.47.

Natera Price Performance

Shares of NASDAQ NTRA opened at $215.09 on Thursday. The stock has a market capitalization of $30.61 billion, a price-to-earnings ratio of -140.58 and a beta of 1.57. Natera, Inc. has a 12 month low of $131.81 and a 12 month high of $256.36. The firm’s 50 day simple moving average is $202.02 and its 200-day simple moving average is $214.75.

Natera (NASDAQ:NTRA) last posted its earnings results on Thursday, February 26th. The medical research company reported $0.35 EPS for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.81. Natera had a negative return on equity of 15.28% and a negative net margin of 9.03%.The firm had revenue of $665.50 million for the quarter, compared to analysts’ expectations of $600.68 million. During the same period last year, the firm earned ($0.41) EPS. Analysts anticipate that Natera, Inc. will post -1.71 earnings per share for the current fiscal year.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.